Navigation Links
Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/10/2008

- Presentation to be Webcast -

MONTVALE, N.J. ,Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista will present at the upcoming 10th Annual Investor Forum on Tuesday, November 11, at 2:25 p.m. Eastern Time. The event will be held November 10th - 12th at the New York Palace Hotel in New York City.

Dr. Berkowitz will discuss the company's planned commercialization of its haptoglobin test kit for diabetes and ongoing Phase 2 initiatives for alagebrium in heart failure. He will also provide an update of recent milestones.

The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com. Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes, a disease affecting almost 7 million patients in the United States. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of Vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.

Synvista Therapeutics is developing oral ant
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
2. Synvista Therapeutics Posts Letter to Stockholders on Web Site
3. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
8. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
9. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
10. Synvista Therapeutics to be Featured on Wallst.net
11. Synvista Therapeutics to Present at the BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Dr. Pollard Brings the Highest Level of Clinical ... Feb. 1 Genetic,Immunity(R), a US/Hungarian clinical-stage biopharmaceutical ... patented,immunotherapeutic platform technology, announced that it has appointed,Richard ... Dr. Pollard has been a leader in HIV/AIDS ...
... N.J., Feb. 1 Amicus Therapeutics,Inc. (Nasdaq: FOLD ... Executive Officer, will present a corporate update at the ... York, NY on Thursday, February 7, 2008 at 11:40 ... The presentation will be webcast live and may be ...
... 31 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... of common stock at a price of $27.00,per share. ... The underwriters,have an option to purchase up to an ... is expected to close on February 6,2008, subject to ...
Cached Biology Technology:Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 2Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer 3Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 3Rigel Announces Pricing of Public Offering of Common Stock 2
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... PHILADELPHIA -- Scientists are another step closer to ... there are factors inside tumors that can slow their ... Cancer Research , a journal of the American Association ... researcher at the division of experimental medicine at the ...
... A recent study led by researchers at Boston University School ... mortality among patients diagnosed with severe sepsis and new-onset atrial ... assistant professor of medicine at BUSM and a pulmonologist at ... study, which will be published in the Journal of the ...
... SAN FRANCISCO Combining the investigational agents REGN910 ... effects in animal models compared with either agent ... International Conference: Molecular Targets and Cancer Therapeutics, held ... findings suggest that combining REGN910 (SAR307746) and aflibercept ...
Cached Biology News:BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death 2Combination therapy shows potent tumor growth inhibition in preclinical studies 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: